Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Regulators of mitosis have been successfully targeted to enhance response to taxane chemotherapy. Here, we show that the salt inducible kinase 2 (SIK2) localizes at the centrosome, plays a key role in the initiation of mitosis, and regulates the localization of the centrosome linker protein, C-Nap1, through S2392 phosphorylation. Interference with the known SIK2 inhibitor PKA induced SIK2-dependent centrosome splitting in interphase while SIK2 depletion blocked centrosome separation in mitosis, sensitizing ovarian cancers to paclitaxel in culture and in xenografts. Depletion of SIK2 also delayed G1/S transition and reduced AKT phosphorylation. Higher expression of SIK2 significantly correlated with poor survival in patients with high-grade serous ovarian cancers. We believe these data identify SIK2 as a plausible target for therapy in ovarian cancers.

Original publication

DOI

10.1016/j.ccr.2010.06.018

Type

Journal article

Journal

Cancer Cell

Publication Date

09/08/2010

Volume

18

Pages

109 - 121

Keywords

Antineoplastic Agents, Phytogenic, Cell Cycle, Centrosome, Female, Humans, Ovarian Neoplasms, Paclitaxel, Phosphorylation, Protein-Serine-Threonine Kinases, Proto-Oncogene Proteins c-akt, RNA, Small Interfering, Spindle Apparatus, Transplantation, Heterologous